Analysts Anticipate Tonix Pharmaceuticals Holding Corp (TNXP) Will Announce Earnings of -$1.28 Per Share
Equities analysts forecast that Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) will report earnings per share (EPS) of ($1.28) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Tonix Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.39) and the highest is ($1.16). Tonix Pharmaceuticals reported earnings per share of ($8.80) during the same quarter last year, which would suggest a positive year-over-year growth rate of 85.5%. The company is expected to report its next quarterly earnings report on Monday, May 13th.
On average, analysts expect that Tonix Pharmaceuticals will report full-year earnings of ($3.99) per share for the current year, with EPS estimates ranging from ($4.00) to ($3.97). For the next year, analysts anticipate that the business will report earnings of ($1.99) per share, with EPS estimates ranging from ($2.37) to ($1.60). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that follow Tonix Pharmaceuticals.
Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings results on Monday, March 18th. The company reported ($6.10) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($3.66) by ($2.44).
TNXP stock traded down $0.03 during trading on Tuesday, hitting $2.31. The company had a trading volume of 732,300 shares, compared to its average volume of 1,371,143. The firm has a market cap of $14.25 million, a price-to-earnings ratio of -0.09 and a beta of 1.91. Tonix Pharmaceuticals has a fifty-two week low of $1.70 and a fifty-two week high of $51.10.
In related news, CEO Seth Lederman purchased 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 26th. The shares were acquired at an average price of $2.38 per share, with a total value of $59,500.00. Following the purchase, the chief executive officer now directly owns 1,767 shares in the company, valued at $4,205.46. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.07% of the stock is owned by insiders.
A number of institutional investors have recently bought and sold shares of TNXP. Bank of New York Mellon Corp acquired a new position in Tonix Pharmaceuticals in the fourth quarter worth $38,000. CVI Holdings LLC acquired a new position in Tonix Pharmaceuticals in the fourth quarter worth $36,000. Finally, Citigroup Inc. acquired a new position in Tonix Pharmaceuticals in the fourth quarter worth $34,000. 8.58% of the stock is currently owned by institutional investors.
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and to improve biodefense. Its lead product candidate is TNX-102 SL or Tonmya that is designed as a bedtime administration for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population.
See Also: How Does the Quiet Period Work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.